Markets:

Overview

News

Currencies

International

Treasuries

Kura Oncology, Inc. - Common Stock (NQ:KURA)

11.21 +0.53 (+4.92%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Kura Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Kura Scores A Big Win As FDA Approves Its New Leukemia Pill ↗

November 14, 2025

Komzifti wins full FDA approval for NPM1-mutated AML, supported by KOMET-001 data, as Wedbush boosts Kura Oncology's price target to $38.

Via Benzinga

Kura Oncology Stock Ignites Retail Frenzy After FDA Clears First Daily Pill For Relapsed Leukemia Patients ↗

November 14, 2025

The FDA approved KOMZIFTI, a once-daily oral therapy for relapsed or refractory NPM1-mutated AML.

Via Stocktwits

Tech's AI Surge Meets Pharma's Resilient Recovery: A Tale of Two Markets in Late 2025

November 05, 2025

The financial markets as of November 5, 2025, present a compelling dichotomy with the technology and pharmaceutical sectors charting distinct yet largely positive courses. While technology continues...

Via MarketMinute

Kura Oncology (NASDAQ:KURA) Reports Q3 2025 Revenue Miss But Narrower-Than-Expected Loss ↗

November 04, 2025

Kura Oncology reported a Q3 2025 revenue miss but a narrower loss. Investors focus on the upcoming FDA decision for its lead drug, ziftomenib, a key catalyst.

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

KURA Stock Rises Pre-Market After Receiving Milestone Payment Related To Cancer Drug Development Agreement ↗

October 24, 2025

Via Stocktwits

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

Kura Oncology Scores $30 Million Boost As New Leukemia Drug Enters Major Trial ↗

October 24, 2025

Kura Oncology rises after $30M milestone from Kyowa Kirin; Phase 3 ziftomenib dosing and FTI data at ESMO bolster pipeline.

Via Benzinga

Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data

October 03, 2025

Boston, MA – October 3, 2025 – Leap Therapeutics, Inc. (NASDAQ: LPTX) experienced a sharp downturn in its stock performance today, with shares falling by over 20% in intraday trading. This significant...

Via MarketMinute

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2025

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

September 09, 2025

Via Benzinga

Uncovering Potential: Kura Oncology's Earnings Preview ↗

April 30, 2025

Via Benzinga

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth ↗

September 04, 2025

Syndax shares gained support after Guggenheim issued a Buy rating, citing strong Q2 results, Revuforj growth, and long-term profit potential.

Via Benzinga

This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

September 04, 2025

Via Benzinga

Evolv Technologies, Precigen, Hesai Group And Other Big Stocks Moving Higher On Friday ↗

August 15, 2025

Via Benzinga

Kura (KURA) Revenue Drops 61% ↗

August 07, 2025

Via The Motley Fool

Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

April 01, 2025

Via Benzinga

Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe ↗

February 12, 2025

Via Stocktwits

Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies ↗

February 06, 2025

Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA submission set for Q2 2025.

Via Benzinga

These stocks are moving in today's after hours session ↗

February 05, 2025

After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 21, 2024

Via Benzinga

Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results ↗

November 21, 2024

Via Benzinga

Crude Oil Gains 1%; Deere Posts Better-Than-Expected Earnings ↗

November 21, 2024

Via Benzinga

Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings ↗

November 21, 2024

Via Benzinga

Topics Stocks

Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26% ↗

November 21, 2024

Instead of seeking a takeover, the company inked a deal worth up to $1.53 billion for its lead asset.

Via Investor's Business Daily

Maximus Reports Weak Earnings, Joins Atkore, PDD Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

November 21, 2024

Via Benzinga

This Caterpillar Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗

October 14, 2024

Via Benzinga

KURA Stock Earnings: Kura Oncology Beats EPS for Q2 2024 ↗

August 08, 2024

KURA stock results show that Kura Oncology beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.